摘要
目的：比较低剂量国产长春瑞滨（盖诺）持续120h静脉输注与传统的静脉推注疗法联合顺铂治疗晚期非小细胞肺癌（NSCLC）的疗效及毒副反应.方法：127例晚期NSCLC患者随机分为A、B两组.A组66例,盖诺10mg加入NS40ml中静推,然后将盖诺10mg加入NS 500ml中持续静脉输注24h,连续5天,共120h,盖诺总剂量60mg,顺铂总量80mg/m^2,d1（或分次给予）;B组61例,盖诺40mg加入NS 100ml中静滴,d1、d8,顺铂用法用量同前.结果：A、B两组的有效率分别为42.4%和42.6%,中位生存期分别为37周和35周,中位进展时间分别为25周和23周,1年生存率分别为37.8%和36.1%.两组最常见的血液学毒性均为中性粒细胞减少,发生率分别为90.9%和91.8%,无统计学差异,但A组的Ⅲ～Ⅳ度骨髓抑制较B组明显为轻（P＜0.05）.结论：长春瑞滨持续120h静脉输注治疗NSCLC有效率、中位生存时间和1年生存率与静推疗法相似,而毒性较静脉推注为低,同时也降低了治疗费用,值得临床进一步研究.
Objective：To compare the efficacy and toxicity of low dose VNB 120-hour-continuous-infusion regimen with bolus VNB plus cisplatin in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods： 127 NSCLC patients were randomized into two groups： Group A 66 cases, VNB 10mg bolus followed by VNB 10mg continuous infusion over 24 hours for 5 days every 3 weeks, combined with DDP 80mg/m^2 on day 1 ; Group B 61 cases, VNB 40mg bolus on day 1 and day 8, The dose of DDP was the same in two groups. Results：The response rate,median survival,median time to progress and l-year survival rate in group A and group B were 42. 4% vs 42. 6%, 37weeks vs 35weeks, 25weeks vs 23weeks and 37. 8% vs 36. 1%, respectively. Bone-marrow suppression was the most frequent dose-limited toxicity in two groups. The incidence in two groups were 90. 9% vs 91.8%, respectively. No significant difference was identified. However, the incidence of grade Ⅲ-Ⅳ bone marrow suppression in group A was lower than that in group B（ P 〈0. 05 ）. Conclusion：The 120h-continous-infusion regimen, compared with conventional one, has the same response rate, median survival, median time to progress and 1-year survival rate, while toxicity and costs are lower. More investigations are needed for further evaluation.
出处
《临床肿瘤学杂志》
CAS
2006年第3期179-181,184,共4页
Chinese Clinical Oncology
关键词
长春瑞滨
持续静脉输注
非小细胞肺癌
Vinorelbine
Continuous intravenous infusion
Non-small-cell lung cancer
